Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ANAB Anaptysbio Inc
- Stocks
- Healthcare
- NASDAQ: ANAB
Price (delayed)
$23.75
Market cap
$697.79M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.79
Enterprise value
$945.11M
Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients
Highlights
ANAB's revenue is up by 23% from the previous quarter
The company's gross profit rose by 23% QoQ
ANAB's debt is down by 6% from the previous quarter but it is up by 6% YoY
Anaptysbio's equity has plunged by 52% from the previous quarter and by 29% YoY
The company's quick ratio fell by 27% YoY and by 13% QoQ
Key stats
What are the main financial stats of ANAB
Market
Valuations
Earnings
Shares outstanding
29.38M
Market cap
$697.79M
Enterprise value
$945.11M
Price to earnings (P/E)
N/A
Price to book (P/B)
21.41
Price to sales (P/S)
6.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.45
Revenue
$111.87M
Gross profit
$111.87M
Operating income
-$100.29M
Net income
-$140.62M
EBIT
-$140.58M
EBITDA
-$138.18M
Free cash flow
-$109.15M
Per share
Balance sheet
Liquidity
EPS
-$4.79
EPS diluted
-$4.79
Free cash flow per share
-$3.56
Book value per share
$1.11
Revenue per share
$3.65
TBVPS
$13.77
Total assets
$422.05M
Total liabilities
$388.03M
Debt
$345.96M
Equity
$34.02M
Working capital
$319.08M
Debt to equity
10.17
Current ratio
8.25
Quick ratio
8.13
Net debt/EBITDA
-1.79
Margins
Efficiency
Dividend
EBITDA margin
-123.5%
Gross margin
100%
Net margin
-125.7%
Operating margin
-89.6%
Return on assets
-30.8%
Return on equity
-282.5%
Return on invested capital
-21.4%
Return on capital employed
-37.2%
Return on sales
-125.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANAB stock price
How has the Anaptysbio stock price performed over time
Intraday
-0.54%
1 week
1.58%
1 month
0.98%
1 year
-4.62%
YTD
79.38%
QTD
6.98%
Financial performance
How have Anaptysbio's revenue and profit performed over time
Revenue
$111.87M
Gross profit
$111.87M
Operating income
-$100.29M
Net income
-$140.62M
Gross margin
100%
Net margin
-125.7%
The company's operating margin has surged by 87% YoY and by 29% QoQ
ANAB's net margin has soared by 82% YoY and by 21% from the previous quarter
ANAB's operating income is up by 38% year-on-year and by 13% since the previous quarter
ANAB's revenue is up by 23% from the previous quarter
Price vs fundamentals
How does ANAB's price correlate with its fundamentals
Growth
What is Anaptysbio's growth rate over time
Valuation
What is Anaptysbio stock price valuation
P/E
N/A
P/B
21.41
P/S
6.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.45
ANAB's EPS is up by 22% year-on-year and by 6% since the previous quarter
ANAB's P/B is 164% higher than its 5-year quarterly average of 8.1 but 17% lower than its last 4 quarters average of 25.7
Anaptysbio's equity has plunged by 52% from the previous quarter and by 29% YoY
The stock's price to sales (P/S) is 79% less than its 5-year quarterly average of 31.0 and 47% less than its last 4 quarters average of 12.2
ANAB's revenue is up by 23% from the previous quarter
Efficiency
How efficient is Anaptysbio business performance
ANAB's return on sales has surged by 82% year-on-year and by 21% since the previous quarter
Anaptysbio's return on equity has shrunk by 75% YoY and by 3.5% QoQ
The ROA has increased by 12% YoY and by 4% QoQ
The return on invested capital has increased by 6% year-on-year and by 2.3% since the previous quarter
Dividends
What is ANAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANAB.
Financial health
How did Anaptysbio financials performed over time
The total assets is 9% more than the total liabilities
The current ratio has declined by 28% year-on-year and by 13% since the previous quarter
The company's quick ratio fell by 27% YoY and by 13% QoQ
ANAB's debt to equity has surged by 95% since the previous quarter and by 48% year-on-year
Anaptysbio's equity has plunged by 52% from the previous quarter and by 29% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.